We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biopharmaceutical Partners Seek Alternatives to Glucocorticoid Steroid Drugs

By LabMedica International staff writers
Posted on 28 Sep 2015
Print article
Collaboration between American and Japanese biopharmaceutical companies is expected to lead to the development of a new class of small molecule drugs for treatment of hematological and inflammatory diseases.

Gencia LLC (Charlottesville, VA, USA) and Takeda Pharmaceutical Company Ltd. (Osaka, Japan) announced the formation of a partnership to develop a class of drugs called mitochondrial agonists of the glucocorticoid receptor (MAGR). These compounds offer the therapeutic potential of conventional glucocorticoid steroids but are chemically distinct and function differently than steroids.

The initial aim of the collaboration will be joint research and development leading to two preclinical drug candidates, one each in the areas of inflammation and oncology. Takeda will establish parameters for conducting clinical trials for drug candidates identified by the partnership. Gencia will receive upfront payments from Takeda as well as preclinical milestones for the two initial compounds and aggregate clinical, commercialization, and sales milestones worth up to approximately 500 million USD. Gencia also will receive royalties on sales of any successfully commercialized products arising from the partnership.

“This collaboration and license agreement with Takeda marks an important milestone in the growth and development of our company,” said Allen Cunningham, president and CEO of Gencia. “Takeda’s strength in drug discovery and development, and in particular their commitment to oncology and inflammation drug research, provides Gencia with the opportunity to advance our mitochondrial targeting platform and MAGR compounds into the clinic, and ultimately to patients in need of these therapies. We are very pleased to have Takeda as our partner in this endeavor.”

Dr. Tetsuyuki Maruyama, head of the pharmaceutical research division at Takeda, said, “We are delighted to partner with Gencia to create new medicines designed to be chemically and functionally different from steroids, but that may still be effective in treating a broad spectrum of diseases for which chronic steroids are currently prescribed. We expect to change the paradigm for how patients are treated by potentially avoiding the issues that result from long-term steroid use.”

Related Links:

Gencia LLC
Takeda Pharmaceutical Company Ltd.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.